Keybank National Association OH boosted its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 50.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,734 shares of the company’s stock after purchasing an additional 4,254 shares during the period. Keybank National Association OH’s holdings in Ionis Pharmaceuticals were worth $641,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Steward Partners Investment Advisory LLC purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $100,000. Parallel Advisors LLC boosted its stake in shares of Ionis Pharmaceuticals by 60.3% during the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after purchasing an additional 1,250 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Ionis Pharmaceuticals by 9.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the period. CIBC Asset Management Inc purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $212,000. Finally, OxFORD Asset Management LLP purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $222,000. 91.01% of the stock is owned by institutional investors and hedge funds.
Ionis Pharmaceuticals Inc (NASDAQ IONS) opened at $51.03 on Friday. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. The company has a market capitalization of $6,368.34, a P/E ratio of 340.20 and a beta of 2.53. Ionis Pharmaceuticals Inc has a twelve month low of $37.26 and a twelve month high of $65.51.
A number of analysts have recently weighed in on the company. Sanford C. Bernstein reissued a “market perform” rating and set a $55.00 price objective (down previously from $61.00) on shares of Ionis Pharmaceuticals in a research note on Tuesday, February 20th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. BidaskClub lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. BMO Capital Markets increased their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Finally, Morgan Stanley increased their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $50.62.
In related news, SVP C Frank Bennett sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $52.50, for a total transaction of $656,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph Klein III sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $48.99, for a total value of $146,970.00. Following the transaction, the director now owns 11,339 shares of the company’s stock, valued at approximately $555,497.61. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 124,635 shares of company stock valued at $6,482,681. 2.13% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://transcriptdaily.com/2018/02/25/keybank-national-association-oh-raises-holdings-in-ionis-pharmaceuticals-inc-ions.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.